Patients with metastatic breast cancer or HER2-, non-metastatic Breast Cancer are being recruited for participation in a research study involving chemotherapy and an inhibitor

IRB/UVA Tracking #
20218
Principal Investigator
Patrick M Dillon
Contact
Olena Glushakova
Contact Email
Contact Phone
434.409.6206
Official Trial Title
A Pilot Study of the Combination of Entinostat with Capecitabine in Metastatic and High Risk Breast Cancer after Neo-adjuvant Therapy
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for adults ages 18 and over who have metastatic (cancer has spread to other parts of the body) breast cancer or human epidermal growth factor 2 negative (HER2-), non-metastatic breast cancer. The purpose of this study is to learn about the safety and side effects of combining entinostat, an investigational drug, with capecitabine, a drug commonly used in breast cancer (BC), in both participants with metastatic breast cancer (MBC) and then participants with high-risk breast cancer after neo-adjuvant therapy.

Participation may last up to 8 months. This includes screening, treatment, and end of treatment visits. You will be contacted on an annual basis after completing treatment for up to 10 years. Study specific tests will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03473639

Compensation

N/A